Advertisement

The overall survival of breast cancer patients without adjuvant therapy

  • Sakura Onishi
  • Masataka SawakiEmail author
  • Junko Ishiguro
  • Ayumi Kataoka
  • Madoka Iwase
  • Kayoko Sugino
  • Yayoi Adachi
  • Naomi Gondo
  • Haruru Kotani
  • Akiyo Yoshimura
  • Masaya Hattori
  • Keitaro Matsuo
  • Yasushi Yatabe
  • Hiroji Iwata
Original Article
  • 14 Downloads

Abstract

Purpose

There are little data regarding the overall survival (OS) of patients without adjuvant systemic therapy, because most patients have been subject to standardized systemic therapies. We evaluated the baseline risk to facilitate making decisions about adjuvant therapy.

Patients and methods

A total of 1835 breast cancer patients who did not receive adjuvant systemic therapy between 1964 and 1992 were retrospectively evaluated. We investigated the 10-year disease-free survival (DFS) and OS according to the number of metastatic lymph nodes, pathological T classification, stage, and estrogen receptor (ER) status.

Results

Survival curves showed that as the number of metastatic lymph nodes, pathological T classification, and staging increased, the 10-year OS and DFS decreased. In univariate and multivariable analyses, the number of metastatic lymph nodes was significantly associated with the DFS and OS, while in a univariate analysis, the pathological T classification and stage were significantly associated with the DFS and OS. ER positivity was a good prognostic factor for the 5-year DFS. However, between 6 and 7 years after surgery, ER negativity was a better prognostic factor than ER positivity.

Conclusion

We showed survival rates of patients without adjuvant therapy according to TNM classification and ER status. This information can aid in treatment selection for doctors and patients through a shared decision-making approach.

Keywords

Breast cancer Overall survival Adjuvant therapy Shared decision making 

Notes

Funding

We report no financial support.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

References

  1. 1.
    Bonneterre J, Roche H, Kerbrat P, Bremond A, Fumoleau P, Namer M, et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2005;23:2686–93.CrossRefGoogle Scholar
  2. 2.
    Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–44.CrossRefGoogle Scholar
  3. 3.
    Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM. Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ. 2015;351:h4901.CrossRefGoogle Scholar
  4. 4.
    Goldhirsch A, Coates A, Gelber R, Glick J, Thurlimann B, Senn HJ. First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol. 2006;17:1772–6.CrossRefGoogle Scholar
  5. 5.
    Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980–91.CrossRefGoogle Scholar
  6. 6.
    Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12:R1.CrossRefGoogle Scholar
  7. 7.
    Bhoo-Pathy N, Yip CH, Hartman M, Saxena N, Taib NA, Ho GF, et al. Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients. Eur J Cancer. 2012;48:982–9.CrossRefGoogle Scholar
  8. 8.
    Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116:5336–9.CrossRefGoogle Scholar
  9. 9.
    Kiba T, Inamoto T, Nishimura T, Ueno M, Yanagihara K, Teramukai S, et al. The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I–III) 3 years after surgery. BMC Cancer. 2008;8:323.CrossRefGoogle Scholar
  10. 10.
    Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol. 2011;29:2301–4.CrossRefGoogle Scholar
  11. 11.
    Cossetti RJ, Tyldesley SK, Speers CH, Zheng Y, Gelmon KA. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. J Clin Oncol. 2015;33:65–73.CrossRefGoogle Scholar
  12. 12.
    Ito Y, Miyashiro I, Ito H, Hosono S, Chihara D, Nakata-Yamada K, et al. Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci. 2014;105:1480–6.CrossRefGoogle Scholar
  13. 13.
    Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–46.CrossRefGoogle Scholar
  14. 14.
    Yu KD, Wu J, Shen ZZ, Shao ZM. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy. J Clin Endocrinol Metab. 2012;97:E2201-9.CrossRefGoogle Scholar
  15. 15.
    Thorpe SM. Monoclonal antibody technique for detection of estrogen receptors in human breast cancer: greater sensitivity and more accurate classification of receptor status than the dextran-coated charcoal method. Cancer Res. 1987;47:6572–5.Google Scholar
  16. 16.
    Andersen J, Orntoft TF, Poulsen HS. Immunohistochemical demonstration of estrogen receptors (ER) in formalin-fixed, paraffin-embedded human breast cancer tissue by use of a monoclonal antibody to ER. J Histochem Cytochem. 1988;36:1553–60.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Sakura Onishi
    • 1
  • Masataka Sawaki
    • 1
    Email author
  • Junko Ishiguro
    • 1
  • Ayumi Kataoka
    • 1
  • Madoka Iwase
    • 1
  • Kayoko Sugino
    • 1
  • Yayoi Adachi
    • 1
  • Naomi Gondo
    • 1
  • Haruru Kotani
    • 1
  • Akiyo Yoshimura
    • 1
  • Masaya Hattori
    • 1
  • Keitaro Matsuo
    • 2
  • Yasushi Yatabe
    • 3
  • Hiroji Iwata
    • 1
  1. 1.Department of Breast OncologyAichi Cancer Center HospitalNagoyaJapan
  2. 2.Division of Molecular and Clinical EpidemiologyAichi Cancer Center Research InstituteNagoyaJapan
  3. 3.Department of Pathology and Molecular DiagnosticsAichi Cancer Center HospitalNagoyaJapan

Personalised recommendations